Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2013 (2013), Article ID 107302, 9 pages
http://dx.doi.org/10.1155/2013/107302
Research Article

Design, Synthesis, and Acetylcholinesterase Inhibition Assay of Novel 9-(1-(Substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine Derivatives

1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, China
2Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, China

Received 22 May 2013; Revised 9 August 2013; Accepted 13 August 2013

Academic Editor: Marco Radi

Copyright © 2013 Dongwei Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Enz, R. Amstutz, H. Boddeke, G. Gmelin, and J. Malanowski, “Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease,” Progress in Brain Research, vol. 98, pp. 431–438, 1993. View at Google Scholar · View at Scopus
  2. G. R. Proctor and A. L. Harvey, “Synthesis of tacrine analogues and their structure-activity relationships,” Current Medicinal Chemistry, vol. 7, no. 3, pp. 295–302, 2000. View at Google Scholar · View at Scopus
  3. H. Sugimoto, Y. Iimura, Y. Yamanishi, and K. Yamatsu, “Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds,” Journal of Medicinal Chemistry, vol. 38, no. 24, pp. 4821–4829, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. D. L. Bai, X. C. Tang, and X. C. He, “Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease,” Current Medicinal Chemistry, vol. 7, no. 3, pp. 355–374, 2000. View at Google Scholar · View at Scopus
  5. J. Winkler, L. J. Thal, F. H. Gage, and L. J. Fisher, “Cholinergic strategies for Alzheimer's disease,” Journal of Molecular Medicine, vol. 76, no. 8, pp. 555–567, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Musiał, M. Bajda, and B. Malawska, “Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment,” Current Medicinal Chemistry, vol. 14, no. 25, pp. 2654–2679, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Mohamed and P. P. Rao, “Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 12, pp. 3606–3609, 2010. View at Google Scholar
  8. T. Mohamed, X. Zhao, L. K. Habib, J. Yang, and P. P. Rao, “Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregationinhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 7, pp. 2269–2281, 2011. View at Google Scholar
  9. T. Mohamed, J. C. Yeung, and P. P. Rao, “Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: synthesis and biological evaluation,” Bioorganic & Medicinal Chemistry Letters, vol. 21, pp. 5881–5887, 2011. View at Google Scholar
  10. T. Mohamed, J. C. Yeung, M. S. Vasefi, M. A. Beazely, and P. P. Rao, “Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template,” Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 14, pp. 4707–4712, 2012. View at Google Scholar
  11. P. V. Reddy, N. G. Nair, M. A. Smith, and W. Kudo, “Purine-based triazoles,” WO2012051296A2.
  12. J. J. Cui, M. Tran-Dubé, H. Shen et al., “Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK),” Journal of Medicinal Chemistry, vol. 54, no. 18, pp. 6342–6363, 2011. View at Publisher · View at Google Scholar · View at Scopus